RPRX Royalty Pharma plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1802768 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.4%
TTM net income YoY-12.1%
TTM EPS YoY-12.6%
Revenue 3-yr CAGR4.0%
Net income 3-yr CAGR53.8%
Margins
Gross margin—
Operating margin57.1%
Net margin25.7%
FCF margin—
EBITDA margin57.3%
Returns
ROE10.1%
ROA3.5%
ROIC (approx.)10.2%
Asset turnover0.13x
Leverage & solvency
Liabilities / assets49.7%
Debt / equity1.26x
Current ratio1.29x
Interest coverage4.02x
Cash quality & payout
Operating cash flow / net income4.41x
Accruals ratio-11.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.38B | $2.26B |
| R&D expense | $452.00M | $2.00M |
| SG&A expense | $573.48M | $236.67M |
| Operating income | $1.56B | $1.29B |
| Interest expense | $307.66M | $225.51M |
| Pretax income | $1.32B | $1.33B |
| Income tax | $0 | $0 |
| Net income | $770.95M | $858.98M |
| EBITDA | $1.56B | $1.29B |
| EPS (basic) | 1.79 | 1.92 |
| EPS (diluted) | 1.78 | 1.91 |
| Dividends declared per share | — | 0.84 |
| Weighted avg. shares (diluted) | 564.46M | 594.11M |
| Balance sheet | ||
| Cash & equivalents | $618.70M | $929.03M |
| Short-term investments | $18.80M | $58.20M |
| Current assets | $1.53B | $1.80B |
| Goodwill | $924.63M | $0 |
| Total assets | $19.62B | $18.22B |
| Current liabilities | $636.21M | $1.25B |
| Short-term debt | $380.00M | $997.77M |
| Long-term debt | $8.57B | $6.61B |
| Total debt | $8.95B | $7.61B |
| Total liabilities | $9.91B | $7.88B |
| Shareholders' equity | $6.48B | $6.95B |
| Net debt | $8.33B | $6.68B |
| Cash flow statement | ||
| Operating cash flow | $2.49B | $2.77B |
| Investing cash flow | -$1.61B | -$2.68B |
| Financing cash flow | -$1.19B | $361.14M |
| Depreciation & amortization | $3.85M | $0 |
| Stock-based compensation | $289.89M | $2.34M |
| Share buybacks | $1.23B | $229.65M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.